Public Health Reports / 2008 Supplement 3 / Volume 123
Approximately one-fourth of the one million to 1.2 million people infected with human immunodeficiency virus (HIV) in the United States may be unaware of their infection. 1, 2 Those people are missing the opportunity to receive lifesaving antiretroviral therapy and take preventive measures to reduce HIV transmission. Some studies have estimated that HIV transmission from people unaware of their infection accounts for about half of the new HIV infections each year. 1, 3, 4 In addition, many newly identified HIV-infected people are diagnosed late in the course of disease. [5] [6] [7] [8] [9] Several studies have found that these late testers (particularly those from certain minority groups) and patients unaware of their HIV infection make multiple contacts with health-care systems during the years prior to diagnosis. [10] [11] [12] [13] In particular, the emergency department (ED) often serves as the primary source for medical care for these populations. 11, 14, 15 HIV screening in the ED and other health-care settings has proved to be feasible. [16] [17] [18] [19] Knowledge of the prevalence and characteristics of patients with unknown HIV infection is critical for informing the development of screening guidelines and approaches in ED settings. Studies performed in the U.S. suggest that the prevalence of HIV infection among patients seeking care in the ED ranges from 2% to 17%, with a prevalence of unknown HIV infection ranging from 1% to 5%. 16, 20 However, most of those studies are outdated. Acute HIV infection refers to the highly infectious period, typically one to six weeks in HIV-infected patients, between exposure to HIV and the development of detectable antibodies against HIV. During that period, approximately half of HIV-infected patients develop a variety of symptoms that, in many cases, precipitate encounters with an ED. 21 Although some experts believe that acute HIV screening should be implemented in EDs and urgent care settings, very few studies have looked into the prevalence of acute HIV infection in EDs in the U.S. [22] [23] [24] To determine the best HIV screening strategy in any given population, an accurate description of the prevalence and characteristics of individuals with unknown HIV infection in such a population is highly desirable. 18 A limited number of studies have looked directly into the prevalence and risk factors of HIVinfected patients seeking care in EDs who are unaware of their infection. 18, 19, 25 To evaluate the potential for the implementation of routine screening, we determined the prevalence of unknown HIV infection among patients being seen in our urban public hospital ED.
METHODS

Study design
We conducted a cross-sectional, unlinked HIV seroprevalence survey among patients with unknown or negative HIV serostatus who had blood drawn for routine medical care at the San Francisco General Hospital (SFGH) ED during March 2007.
Population and procedures
The survey included all patients seeking medical attention at the SFGH ED during the study period who had blood specimens collected as a part of their routine medical care. The SFGH ED receives approximately 50,000 patient visits per year, predominantly from individuals who are uninsured (30%) or receiving public insurance (40%). It is the only level I trauma center in San Francisco City and County (population 780,000). We determined the HIV status of patients by reviewing medical records dated from January 1996 through March 2007. We categorized patients as HIV-infected if medical records included (1) a positive HIV enzyme immunoassay (EIA) test; (2) a positive HIV Western blot test; (3) a positive HIV RNA test; (4) mention of any HIV diagnosis and/or acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection by International Classification of Diseases, 9th and 10th Revisions (ICD-9 and ICD-10) coding; (5) HIV-related medical care visit at the SFGH Medical Center; or (6) any prescription for highly active antiretroviral therapy.
In patients without any documentation of HIV infection, we de-identified patient whole-blood specimens and tested those for HIV infection by HIV antibody. Negative HIV-antibody specimens were further tested for the presence of HIV RNA. We reviewed hospital and laboratory databases up to three months after the last patient visit to determine any new HIV diagnosis after the ED encounter. The number of visits to the ED, urgent care clinic, and other health-care settings associated with the SFGH Medical Center during the 30 days before and the 30 days after the ED encounter were measured. Only clinical encounters recorded in The Health Records Electronic Data Set (THREDS, described later in this article) were used in this study.
Given that no standard definition for frequent visitors to the ED is available, patients with more than one ED encounter during the study period (30 days) were considered patients with frequent visits to the ED and were compared with patients with only one ED encounter. For all patients, we analyzed encounters with the health-care system during the 30 days before the first ED encounter and the 30 days after the last ED encounter. Unclassified patients were defined as patients for whom some basic information (first and last name) was lacking during the ED encounter. These patients were a heterogeneous group of people consisting usually of unconscious patients, trauma victims, and/or other patients with an impaired level of consciousness, as well as those with lack of documentation that prevented their identification on triage.
Five different databases were sequentially generated to ensure that no linkage of HIV test results to identifying patient information was possible. First, a database with the patient's demographic characteristics, medical chart information, and SFGH clinical laboratory results was created. This database did not include the unique study identification number. Second, a temporary linkage database consisting of SFGH medical record numbers and the unique study identification number was created. Third, a database was created containing the unique study identification number linked to the patient demographic and clinical data. This database contained no personal identifiers. Fourth, the San Francisco Department of Public Health (SFDPH) Laboratory tested blood specimens identified only by the unique study identification number. After we confirmed that all patient information was accurate and complete, the first two databases (the only ones containing any personal identifiers and/or allowing linkage to personal identifiers) were permanently destroyed and HIV testing was started. Finally, we created a fifth database by merging the database with the study identification number and patient characteristics with the SFDPH Laboratory database containing the results of the HIV testing for analysis.
Data source
We obtained all patient information from THREDS from the University of California, San Francisco (UCSF) Clinical and Translational Science Institute (CTSI) Clinical Research Center at SFGH and from manual review of the individual hospital medical records.
Laboratory testing
Patient plasma samples were screened for HIV antibodies by EIA (Genetic Systems ™ HIV-1/HIV-2 Plus O EIA, Bio-Rad Laboratories, Hercules, California). Reactive EIA samples were tested for confirmation using an immunofluorescent assay (IFA) (Fluorognost HIV-1 IFA, Sanochemia Pharmazeutika AG, Vienna, Austria). Samples with discordant EIA and IFA results were further evaluated by testing for HIV-1 RNA using Transcription Mediated Amplification (TMA, Aptima HIV-1 RNA Qualitative Assay, Gen-Probe Inc., San Diego, California). Patients with reactive EIA samples that tested IFA and TMA negative were considered not infected with HIV. All confirmed positive samples were tested by an EIA modified to be less sensitive (Vironostika-LS HIV-1 Microelisa, BioMérieux Inc., Durham, North Carolina) as utilized in the Serologic Testing Algorithm for Determining Recent HIV Seroconversion (STARHS) method to look for evidence suggestive of recent infection. 26, 27 All testing was performed at the SFDPH Laboratory. HIV antibody-negative specimens were tested with a pooled RNA screening protocol by Abbott real-time polymerase chain reaction (PCR) assay (Abbott Laboratories, Abbott Park, Illinois).
Outcomes
The primary outcome of our study was the prevalence of unknown HIV infection. Potential correlates of unknown infection included age, sex, race/ethnicity, health insurance status, marital status, primary language, previous HIV testing, frequency of visits to the ED and urgent care clinic during the prior 30 days, homelessness status, and admission to the hospital.
Statistical analyses
Given that a patient could have multiple visits to the ED without increasing the number of patients with unknown HIV infection during the study period, all analyses were performed at the patient level (as opposed to the visit level). The prevalence of unknown HIV infection and 95% confidence intervals (CIs) were determined by standard methods. Odds ratios were calculated for all factors potentially associated with unknown HIV infection. We controlled for possible confounding or effect-modifying factors by creating a logistic regression model using backward stepwise elimination. We determined variables included in the logistic regression analysis a priori based on estimation of their significance as epidemiologic factors during the preliminary crude analysis (significant at p#0.05) and biological plausibility. The model included all of the following variables: age, sex, health insurance status, race/ethnicity, previous HIV testing, marital status, frequency of visits to the ED and urgent care clinic during the prior 30 days, homelessness status, primary language, and admission to the hospital. A two-sided p-value ,0.05 was considered statistically significant, and we used SAS version 9.1 for analyses.
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Human subjects
The UCSF Committee on Human Research approved this study and waived patient consent requirements.
RESULTS
During the study period (March 2007), 1,820 out of 3,673 patients had blood specimens collected at the SFGH ED. Of those 1,820 patients, we determined 146 (8.0%) to be HIV-infected by medical record review. Table 1 shows the characteristics of patients seeking care at the SFGH ED by calendar year 2006, overall for March 2007, and our study sample from March 2007.
Of the 1,674 patient specimens tested among patients not known to be HIV-infected, 15 patients (0.9%, 95% CI 0.55, 1.47) were found to be HIVinfected ( Table 2 ). The characteristics of these 15 patients are shown in Table 3 . One HIV RNA-positive specimen (6.7% of those with unknown HIV infection, 95% CI 1.55, 30.23) was detected among the HIV-1 antibody-negative specimens. Interestingly, seven of the 15 patients (47.0%) with unknown HIV infection had at least one other visit to the ED or the urgent care clinic during the previous month. Furthermore, three (20.0%) were admitted to the hospital and discharged without an HIV diagnosis. None of the unknown HIVinfected patients had evidence of recent infection by detuned EIA and, therefore, were likely to have chronic (not recent) HIV infection.
The odds ratios for selected factors associated with unknown HIV infection are shown in Table 4 . Being male and homeless were significantly associated with unknown HIV infection ( Table 4 ). In the multivariate analysis, being homeless and aged 18 to 30 years were found to be statistically associated with unknown HIV infection ( Table 4) . d Unclassified refers to patients for whom some basic information (first and last names) was lacking during the emergency department encounter.
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DISCUSSION
In our cross-sectional, unlinked HIV-prevalence study, we found that 0.9% of the patients seeking care at the SFGH ED had unknown HIV infection. While the overall prevalence of HIV infection in the population was approximately 9.0%, the relative prevalence of unknown HIV infection (approximately 10.0%) was lower than the national estimate of 25.0%. About one out of 10 HIV-infected individuals (10.0%) seeking care at the ED in our institution were HIV-infected and did not know it. Our findings contrast with previous reports suggesting that one-fourth to one-third of patients with HIV infection do not know their serostatus. 2, 29 However, our findings are more consistent with reports from a population-based study in San Francisco showing an overall prevalence of nearly 0.8% of unknown HIV infection. 30 Indeed, our data suggest that using the prevalence of known HIV infection as a surrogate for the estimated prevalence of unknown HIV infection might lead to an overestimation of such prevalence in certain settings. Therefore, routine HIV-testing interventions among nonselected populations might turn out to be much less cost-effective than anticipated. Furthermore, the relatively modest prevalence of unknown HIV infection found in our study suggests either that HIV-infected individuals who are unaware of their infection use health-care services other than the ED in San Francisco or that previous estimates of the proportion of HIV-infected patients unaware of their infection are too high.
Our study population consisted of patients with blood samples taken for routine medical care seeking medical attention at the ED during a one-month period. The unlinked nature of our design allowed us to test for unknown HIV infection among 45% (1,674 out of 3,673 patients) of the patients seen at the ED during that interval, allowing the study of most subgroups of patients. By conducting an unlinked seroprevalence study, we avoided the selection bias generally introduced by studies of other designs, potentially increasing the generalizability of our results. Similarly, the relatively narrow 95% CIs around the point prevalence estimates of the entire sample and of most subgroups are a reflection of the size of the total sample and the distribution of the total sample across the different subgroups, and suggest the accuracy of our prevalence estimates. While our sample reflects the demographic distribution of the patients seen at the ED during March 2007 (the study period) and that of calendar year 2006, given the nature of the design, our sample likely represents the sicker subgroup of those patients. As we would have expected, the patients included in our sample were more likely to be admitted to the hospital when compared with the entire population of patients seeking care at the ED. Thus, although we are confident that our estimates of unknown HIV infection reflect those of the population of patients getting blood drawn for medical care at the ED, it remains unknown if our results are generalizable to the entire population of patients seeking care at the SFGH ED. Furthermore, given that we only included one ED at a county hospital in San Francisco, our results might not be generalizable to other EDs in San Francisco or other cities.
Acute HIV infection in health-care settings may be more common than previously suspected. We found that approximately 7% (one of 15) of the patients with unknown HIV infection presenting to our ED had acute HIV infection. Consistent with our findings, a study performed at an urgent care center in Boston found that 1% (five of 499) of patients presenting with flulike symptoms had acute HIV infection. 22 Similarly, a different study found that when patients undergoing evaluation for mononucleosis with negative heterophile antibody tests were screened, 1% of them had acute HIV infection. 23 Unfortunately, acute HIV infection is rarely considered in the differential diagnosis of patients presenting to EDs, and no screening programs for acute HIV infection of patients seeking care at an ED exist in the U.S. [31] [32] [33] Our results suggest that patients with acute HIV infection might represent a significant proportion of the patients with unknown HIV infection presenting to EDs. Given the potential clinical and public health importance of identifying such patients, the yield and cost-effectiveness of routine, acute-HIV screening programs in EDs and urgent care settings should be evaluated.
Whether routine HIV screening is a cost-effective intervention to detect patients unaware of their HIV infection depends on the prevalence of unknown HIV infection in the population. A recent analysis showed that routine HIV screening is a cost-effective intervention in populations with HIV prevalence of 0.1%, suggesting that routine HIV screening might be a cost-effective measure in our setting. 34 However, the implementation of the Centers for Disease Control and Prevention's (CDC's) recent recommendations on HIV testing 24 without new resources or a reprioritization of existing allocations for HIV testing in busy health-care settings with rapid patient turnover is challenging.
The universal, opt-out, routine HIV screening recommended by CDC is likely to lead to the highest number of new HIV-infected patients detected; however, its implementation is not practical under current CDC funding priorities. The multiple barriers to the implementation of this screening strategy are discouraging to clinicians and public health officials, and preclude the implementation of other, simpler, less expensive, targeted HIV screening programs. Targeted HIV screening programs are based on risk factors for HIV infection and, therefore, will miss the diagnosis of HIV-infected individuals lacking those traditional risk factors until later in the course of their disease. However, if targeted, risk-based screening requires fewer resources, as it is often assumed, implementation and sustainability of such targeted screening programs might be more feasible. Furthermore, risk-based HIV screening might allow funds to be directed toward maintaining much-needed prevention case-management services, which studies have shown contribute to better diagnosis, lower transmission rates, and better treatment outcomes. 3, 35 Central to targeted screening is the identification of risk factors. Traditional risk factors for HIV infection include injection drug use, unprotected anal or vaginal sexual intercourse with multiple sex partners, concurrent sexually transmitted infections, and lack of male circumcision. Nevertheless, risk factors vary widely depending on the geographic location and the population, and each ought to be evaluated to match a particular program to a population and maximize the diagnoses of HIV-infected patients. Consistent with the epidemiology of HIV-infected patients diagnosed late in the course of their disease in San Francisco, we found that unknown HIV-infected patients were more likely to be young men from underserved populations. In particular, we found that being male and being homeless were significantly associated with unknown HIV infection in the bivariate analysis. After adjusting for possible confounders in a multivariate model, being younger and being homeless were significantly associated with unknown HIV infection, with a strong but borderline association with being male. Interestingly, Hispanic patients with unknown HIV infection were significantly younger than other racial/ethnic groups, suggesting that the characteristics of patients with unknown HIV infection may vary across different subgroups of the population.
It is important to note, however, that using male sex, homelessness, and younger age as correlates of unknown HIV infection in the population studied might allow targeted screening. If we had implemented HIV screening targeting all homeless patients (men and women) and all men regardless of homelessness status during the study period, we would have detected 100% of the cases with unknown HIV infection by testing 65% of the population. Similarly, by targeting all people with either public health insurance (i.e., Medicare and Medicaid) or no insurance, we would have also detected all cases by testing 93% of our population. However, by restricting our HIV antibody testing to men with either public health insurance or no insurance, we would have detected 13 (93%) out of the 14 cases by testing only 58% of the population. Whether universal screening, with its associated higher costs and increased difficulties in program sustainability, should be implemented to detect the small number of unknown HIV-infected patients who belong to populations not targeted by risk-based screening is ultimately a choice to be determined by each institution and society.
In San Francisco, people diagnosed with AIDS within one year of their HIV diagnosis are more likely to belong to racial/ethnic minority groups, to have no reported risk for HIV infection, to be born outside of the U.S., and to be uninsured, among other risk factors. 8 Other studies have found similar characteristics of late testers in other U.S. cities. 36, 37 In our study, none of the unknown HIV-infected patients had evidence of recent infection by detuned EIA and, therefore, were likely to have chronic (not recent) HIV infection. Importantly, most patients with unknown HIV infection had multiple encounters with the health-care system during the three months prior to the study period and, in some cases, they were even admitted to the hospital. Those encounters clearly represented missed opportunities for diagnosing HIV infection. Our study did not allow us to determine the stage of HIV disease in those patients with unknown HIV infection. However, these results remind us of the potential impact of HIV testing of certain at-risk populations in health-care settings.
Limitations
Several limitations of our study should be acknowledged. The misclassification of individuals with previously diagnosed HIV infection as undiagnosed could have potentially led to an overestimation of the prevalence of patients with unknown HIV infection. We were particularly cautious in this regard and made a comprehensive effort to recognize previously diagnosed HIV-infected patients within our system. However, it was still possible that HIV-infected patients were diagnosed and received care outside the SFGH Medical Center system. Nevertheless, given that all our study patients utilized different health-care services at our institution regularly, it seems unlikely that no record of a previous diagnosis of HIV infection would exist in our system if either the health-care provider or the patient had known the diagnosis. In addition, in clinical practice, not all patients will disclose their known HIV status, and comprehensive review of medical records is unlikely to be standard in EDs. Therefore, a certain proportion of misclassification is also expected in clinical practice and in any HIV screening program.
Although related, the HIV seroprevalence of unknown HIV infection in any given population is not necessarily the same as the diagnostic yield of an HIV screening program implemented in such a population. Given that the latter one drives the determination of any cost-effectiveness of a screening program, any estimation of the cost-effectiveness of a program based on HIV seroprevalence remains speculative. We used electronic records and information collected for reasons other than this study, and it is possible that missing or inaccurate data led to misclassification of patients. However, we have no reason to believe that such misclassification was differential; therefore, it is unlikely to have introduced a significant bias to our results.
CONCLUSIONS
The relative prevalence of unknown HIV infection in our sample of patients from a county hospital ED was lower than expected from prior CDC estimates. However, acutely HIV-infected patients might represent a significant proportion of such patients. These findings suggest that targeted HIV screening strategies in our patient population might have higher diagnostic yield and decreased costs, and ultimately be more sustainable. Acute HIV screening in this setting might be of great clinical and public health importance. However, prospective studies are required to confirm this assertion.
Seroprevalence assessments are a valuable and underutilized tool to guide clinical and public health decisions. Further HIV seroprevalence studies in different populations would be highly valuable in guiding the implementation of HIV screening programs.
